Title
Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse.

Permalink
https://escholarship.org/uc/item/1td1d0v0

Authors
Wang, Derek W
Mokhonova, Ekaterina I
Kendall, Genevieve C
et al.

Publication Date
2018-06-01

DOI
10.1016/j.omtn.2018.02.002

Peer reviewed
Repurposing Dantrolene for Long-Term Combination Therapy to Potentiate Antisense-Mediated DMD Exon Skipping in the mdx Mouse

Derek W. Wang,¹,² Ekaterina I. Mokhonova,¹,²,³ Genevieve C. Kendall,¹,⁴,₅ Diana Becerra,¹,³ Yalda B. Naeini,⁶ Rita M. Cantor,⁴ Melissa J. Spencer,¹,³ Stanley F. Nelson,¹,⁴,⁵,₆,⁷ and M. Carrie Miceli¹,²,⁵,₇

¹Center for Duchenne Muscular Dystrophy, University of California, Los Angeles, Los Angeles, CA, USA; ²Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine and College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA, USA; ³Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ⁴Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA; ⁵Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA; ⁶Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, USA

Duchenne muscular dystrophy (DMD) is caused by mutations in DMD, resulting in loss of dystrophin, which is essential to muscle health. DMD "exon skipping" uses anti-sense oligonucleotides (AONs) to force specific exon exclusion during mRNA processing to restore reading frame and rescue of partially functional dystrophin protein. Although exon-skipping drugs in humans show promise, levels of rescued dystrophin protein remain suboptimal. We previously identified dantrolene as a skip booster when combined with AON in human DMD cultures and short-term mdx dystrophic mouse studies. Here, we assess the effect of dantrolene/AON combination on DMD exon-23 skipping over long-term mdx treatment under conditions that better approximate potential human dosing. To evaluate the dantrolene/AON combination treatment effect on dystrophin induction, we assayed three AON doses, with and without oral dantrolene, to assess multiple outcomes across different muscles. Meta-analyses of the results of statistical tests from both the quadriceps and diaphragm assessing contributions of dantrolene beyond AON, across all AON treatment groups, provide strong evidence that dantrolene modestly boosts exon skipping and dystrophin rescue while reducing muscle pathology in mdx mice (p < 0.0087). These findings support a trial of combination dantrolene/AON to increase exon-skipping efficacy and highlight the value of combinatorial approaches and Food and Drug Administration (FDA) drug re-purposing for discovery of unsuspected therapeutic application and rapid translation.

INTRODUCTION

Duchenne muscular dystrophy (DMD) is the most common lethal genetic disease of childhood, with an incidence that ranges from 10.7 to 27.8 per 100,000 population.¹ DMD is mainly caused by frameshifting multi-exon deletions in the DMD gene, resulting in loss of expression of the encoded protein, dystrophin, which is critical to muscle cell health.² Dystrophin stabilizes the muscle membrane in the context of contraction by linking the cytoskeleton to the extracellular matrix through N-terminal association with F-actin and C-terminal association with the dystrophin-associated glycoprotein complex (DGC). The DGC spans the membrane and binds laminin a2 within the basal lamina and requires dystrophin for its sarcolemmal localization, stability, and function. Additionally, dystrophin and the DGC contribute to muscle cell signaling and stem cell self-renewal.³

Loss of dystrophin and DGC expression results in muscle membrane damage, altered signaling, and defective muscle regeneration. Membrane damage drives increased intracellular Ca²⁺ levels, calpain activation, protein degradation, and cell death.⁴ Proper nitric oxide synthase (NOS) localization at the DGC is lost in the absence of dystrophin, resulting in hyper-nitrosylation of the ryanodine receptor 1 (RyR1),⁵ which also contributes to Ca²⁺ dysregulation. Inflammation and replacement of muscle with fat and fibrosis further interferes with muscle regeneration and function. Over time, this leads to progressive loss of body-wide skeletal muscle and cardiac function. Boys with DMD typically become dependent on a wheelchair between ages 10 and 13 years and often succumb to respiratory and/or cardiac failure between the ages of 18 and 30 years.

Becker muscular dystrophy (BMD), a milder form of dystrophy, is also caused by mutations in DMD.⁶,⁷ However, in most instances, DMD mutations in those with BMD preserve the mRNA reading frame and lead to the production of an internally deleted dystrophin protein with partial functionality. BMD patients can range in severity from loss of ambulation at 16 years old to asymptomatic, depending

Received 5 November 2017; accepted 6 February 2018; https://doi.org/10.1016/j.omtn.2018.02.002.

These authors contributed equally to this work.

Correspondence: M. Carrie Miceli, Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine and College of Letters and Sciences, University of California, Los Angeles, Los Angeles, CA, USA. E-mail: cmiceli@ucla.edu
largely on the stability and functionality of the mutant dystrophin. Of note, several in-frame Becker-causing DMD mutations cluster within a hotspot between exons 45 and 55 and encode internally deleted dystrophin proteins with partial functionality responsible for a milder disease course relative to Duchenne. These findings provide the rationale for therapies aimed at reframing mRNA to rescue Becker-like dystrophin proteins with partial functionality.

One therapeutic strategy, termed exon skipping, forces targeted exon exclusion during pre-mRNA splicing to restore the DMD reading frame through systemic administration of anti-sense oligonucleotides (AONs). Reframing by exon skipping rescues the expression of a BMD-like internally deleted dystrophin. AON-guided DMD exon skipping has proven effective in rescuing a Becker-like dystrophin protein and improving skeletal muscle function in both mouse and dog DMD models.

Exondys51, a morpholino AON designed to restore the DMD reading frame by excluding exon 51, was recently granted accelerated approval in the USA and is relevant to 13% of DMD patients. In a small multi-year study, 12 boys who were amenable to reframing by skipping exon 51 were administered Exondys51 weekly by intravenous infusion. All patients received 30 mg/kg, except for one who received 50 mg/kg. After 3 years, those treated with Exondys51 were reported to walk 151 m further than predicted by a longitudinal natural history of DMD boys from a cohort well-matched for genotype, age, and functional parameters at study initiation. By year 4, only 20% of Exondys51-treated subjects were reported to have lost ambulation, whereas 80% of the matched historical control lost ambulation over the same time frame.

Skeletal muscle biopsies from subjects administered Exondys51 demonstrated a statistically significant induction of dystrophin relative to pre-treatment control biopsies and, ultimately, accelerated approval was granted based on this biomarker. Levels of induced dystrophin ranged from 0% to 2.47% of normal (as determined by western blot), distributed across an average of 16% of myofibers (as determined by immunofluorescence of dystrophin-positive fibers). Although no lower threshold requirement for dystrophin expression has been firmly established, very low levels have been reported to be associated with some functional benefit in mouse models and human DMD/BMD. Some BMD patients have been reported to express as low as 3% of wild-type levels of internally deleted dystrophin. Although these patients present with “severe BMD,” they are less severe than typical DMD. Western blot analysis has not been performed to allow robust quantitation against a human dystrophin protein standard, limiting clear delineation of the lower limit of dystrophin needed for any degree of functional benefit. Nonetheless, induction of higher levels of dystrophin is predicted to impart greater function.

We previously identified dantrolene as a booster of antisense-mediated exon skipping through an unbiased small molecule screen and validated its efficacy in short-term mdx mouse and human DMD myotube culture models. The mdx mouse has a premature termination within exon 23 of DMD, leading to loss of dystrophin and muscular dystrophy. Intravenous administration of e23AON promotes exon 23 skipping and rescue of an internally deleted dystrophin protein that is capable of significant functionality and rescue of the DMD-like phenotype. We have reported that dantrolene (10 mg/kg), administered twice daily intraperitoneally (i.p.), boosted low-dose (10 mg/kg) AON-directed exon 23 skipping (e23AON), dystrophin protein expression, and strength in the mdx mouse over the course of short-term experiments (1–3 weeks). Further, DMD patient-derived reprogrammed myotubes bearing an exon 45–50 deletion treated with the dantrolene/e51AON combination induced greater levels of in-frame skipped DMD exon51 mRNA than either drug alone, establishing potential relevance to human DMD treatment.

Here, we assess if dantrolene has an exon skip boosting activity in the mdx DMD mouse model in the context of long-term 6-month chronic treatment with weekly intravenous (i.v.) e23AON at a high (300 mg/kg), medium (50 mg/kg), or low (10 mg/kg) dose in combination with dantrolene dosed orally. These conditions are more relevant to potential combination therapy in DMD patients currently prescribed Exondys51 or who may be exposed to other AON drugs currently in development. We demonstrate that dantrolene boosts e23AON-directed DMD mRNA exon skipping, dystrophin protein expression, and rescue of dystrophic pathology in mdx mice in the context of long-term chronic treatment, without observed toxicity. These findings provide data in support of the feasibility and efficacy of repurposing dantrolene as a skip-boosting drug for use in combination with exon-skipping AON. Because dantrolene and Exondys51 are both Food and Drug Administration (FDA)-approved drugs with good safety profiles in DMD, combination therapy could be tested in humans.

**RESULTS**

**Orally Administered Dantrolene Enhances Antisense-Mediated Exon Skipping and Dystrophin Protein Rescue in mdx Mice**

Previous studies using twice daily i.p. injections identified dantrolene as a booster of DMD exon skipping in short-term treatment using non-clinical grade dantrolene (Sigma). Dantrolene is already clinically available in tablet form for oral administration under the trade name dantrolium. Because oral dosing is much more practical both for long-term mouse studies and translation to human DMD, we performed a series of 3-week pilot studies to determine if orally administered dantrolene incorporated into chow ad libitum boosted dystrophin induction of systemically administered e23AON. We found that orally administered dantrolene administered in combination with 50 mg/kg e23AON boosted dystrophin immunofluorescence intensity per cross-sectional area relative to e23AON treatment alone (Figure S1). Therefore, we relied on oral dantrolene incorporated into chow to assess dosing, efficacy, and safety during the course of chronic combination treatment.
of dantrolene skip boosting activity was assessed across multiple droplet digital PCR (ddPCR) (Figure 3A). The presence or absence of skipping were determined in the quadriceps and diaphragm using serum BUN levels in all treated groups (Figure 2), this decrease is not likely to be biologically significant. H&E staining did not reveal any differences in pathology of the heart, liver, and kidney associated with e23AON and dantrolene dosing (not shown).

At the beginning of the study, 6- to 8-week-old mice underwent stratified randomization based on age and weight. Mice were acclimated to the facility for 1 week. Then, using a staggered start, cohorts of 9 mice (from random treatment groups) were initiated into the experiment because our workflow is limited to harvest of muscles of 9 mice per day. Mice were weighed weekly and dantrolene chow dose was adjusted to maintain consistent dosing throughout the study. Serum levels of dantrolene were assessed at the end of the treatment period and demonstrated levels of 0.27 ± 0.18 μg/mL were achieved (Figures S2A–S2C).

During the 6-month treatment, mice did not show any change in body weight or feeding habits with dantrolene treatment. Because of the potential for liver and kidney damage upon chronic treatment, we assessed serum levels of γ-glutamyl transferase (GGT), creatinine, bilirubin, and blood urea nitrogen (BUN) 1 week prior to sacrificing animals. We found no significant changes in these measures that were reflective of kidney or liver toxicity (Figure 2) with dantrolene treatment. Although dantrolene treatment did lead to an 18% decrease in serum BUN levels in all treated groups (Figure 2), this decrease is not likely to be biologically significant. H&E staining did not reveal any differences in pathology of the heart, liver, and kidney associated with e23AON and dantrolene dosing (not shown).

6-Month Combination Therapy Promotes Increased Exon Skipping and Dystrophin Expression in Skeletal Muscle

We next assessed the efficacy of long-term administration of combination therapy of e23AON and dantrolene in mdx mice. We designed a blinded, placebo-controlled, multi-dose, 6-month study, in which mdx mice were fed a diet containing 30–70 mg/kg/day dantrolene ad libitum in combination with weekly retro-orbital injections of e23AON at either 0, 10, 50, or 300 mg/kg (Figure 1). Experiments were blinded and performed within recently published guidelines.

The p values for each outcome were then combined over the two muscle types using a meta-analysis. To illustrate, for the Friedman test of quantitative ddPCR readouts for DMD exon 23 skipping, every mouse was ranked across all AON and dantrolene levels, and a model that includes e23AON levels and the presence or absence of dantrolene as well as the possibility of their interaction was tested for both the quadriceps and diaphragm. Results indicate that e23AON has a highly significant positive treatment effect when considered across all e23AON concentrations combined relative to placebo-treated controls in both the quadriceps and diaphragm (p < 0.0001 for each, Figure S3). Further, dantrolene/e23AON combination treatment significantly boosts mRNA exon skipping relative to e23AON treatment alone when all e23AON concentrations tested are considered together (p = 0.012 for quadriceps, p = 0.0008 for diaphragm; Figures 3B and S3). Meta-analysis of the p values from the quadriceps and diaphragm combined demonstrate a higher level of significance of dantrolene/e23AON treatment on exon skipping (p = 0.00012) (Figure 3B).

Dystrophin protein expression in mice treated with combination therapy, both by quantitating the intensity of dystrophin immunofluorescence staining (Figure 4A) and the percentage of dystrophin-positive fibers (Figure 4B) within transverse muscle sections, was also significantly boosted when dantrolene was used in combination with e23AON relative to e23AON alone for dystrophin immunofluorescence intensity in the quadriceps (p = 0.0032) and for dystrophin-positive fibers in the quadriceps (p = 0.0069) and diaphragms (p = 0.0035) (Figures 4A–4D and S4). Statistical significance was not achieved for dystrophin immunofluorescence intensity in the diaphragm when analyzed independently (p = 0.086). However, the meta-analysis of p values from the quadriceps and diaphragm strongly supports an effect of dantrolene in combination with e23AON concentrations and quadriceps and diaphragm muscles. Each outcome was tested separately using the same analytic approach to assess whether dantrolene contributes to that outcome beyond e23AON. Because these outcomes are not normally distributed, a nonparametric two-way ANOVA (Friedman’s test) was used.

The Friedman test of quantitative ddPCR readouts for DMD exon 23 skipping, every mouse was ranked across all AON and dantrolene levels, and a model that includes e23AON levels and the presence or absence of dantrolene as well as the possibility of their interaction was tested for both the quadriceps and diaphragm. Results indicate that e23AON has a highly significant positive treatment effect when considered across all e23AON concentrations combined relative to placebo-treated controls in both the quadriceps and diaphragm (p < 0.0001 for each, Figure S3). Further, dantrolene/e23AON combination treatment significantly boosts mRNA exon skipping relative to e23AON treatment alone when all e23AON concentrations tested are considered together (p = 0.012 for quadriceps, p = 0.0008 for diaphragm; Figures 3B and S3). Meta-analysis of the p values from the quadriceps and diaphragm combined demonstrate a higher level of significance of dantrolene/e23AON treatment on exon skipping (p = 0.00012) (Figure 3B).

Dystrophin protein expression in mice treated with combination therapy, both by quantitating the intensity of dystrophin immunofluorescence staining (Figure 4A) and the percentage of dystrophin-positive fibers (Figure 4B) within transverse muscle sections, was also significantly boosted when dantrolene was used in combination with e23AON relative to e23AON alone for dystrophin immunofluorescence intensity in the quadriceps (p = 0.0032) and for dystrophin-positive fibers in the quadriceps (p = 0.0069) and diaphragms (p = 0.0035) (Figures 4A–4D and S4). Statistical significance was not achieved for dystrophin immunofluorescence intensity in the diaphragm when analyzed independently (p = 0.086). However, the meta-analysis of p values from the quadriceps and diaphragm strongly supports an effect of dantrolene in combination with
e23AON relative to e23AON alone based on dystrophin immunofluorescence (p = 0.0025) and dystrophin-positive fibers (p = 0.00028, Figure 4C). The effect size is considerable in some instances. For example, at 300 mg/kg e23AON, the dantrolene co-administration resulted in an average doubling of dystrophin fluorescence from 13.9% to 27.5% and percentage of positive fibers from 12.6% to 23.1% of levels observed in control C57Bl6 mice in the quadriceps (Figures 4A and 4B).

Combination therapy boosted dystrophin protein expression relative to e23AON treatment alone, as measured by western blot analysis of total protein in the quadriceps (Figures 5A and 5B), with a high level of significance (p = 0.0054, Figures 5C and S5). Increases were on the order of 1%–1.7% of the amount of dystrophin typically observed in non mutant C57Bl6 mice quadriceps (Figures 4A and 4B).

To determine whether the increase in dystrophin observed with co-administration of dantrolene helps promote sarcolemmal DGC protein stability, we assessed the effect of dantrolene on other members of the DGC. Long-term dantrolene combined with e23AON administration rescued the sarcolemmal localization of both α-sarcoglycan and β-dystroglycan, indicators of DGC rescue. Figure 6 shows images from the 50 mg/kg e23AON treatment group (Figure 6); similar results were seen at 10 mg/kg and 300 mg/kg e23AON (data not shown). Immunostaining of skeletal muscle demonstrated positive staining at the N terminus, rod domain, and C terminus of dystrophin (Figure S6). Serial sections of the quadriceps and diaphragm indicate that dystrophin-positive fibers colocalized with fibers expressing DGC proteins. Together, these findings demonstrate that dantrolene boosts e23AON activity during long-term treatment to facilitate restoration of dystrophin protein, with sufficient functionality to enable DGC rescue and localization to the sarcolemma.

Dantrolene/e23AON Combination Therapy Reverses Pathology to a Greater Extent than e23AON Alone

Serum creatine kinase (CK) levels are an indicator of muscle fiber integrity because muscle CK leaks into the serum upon membrane damage. After 6 months of treatment, serum CK levels in mdx mice were reduced in response to e23AON, as expected. These levels were further reduced significantly with daily oral dantrolene supplementation across all e23AON treatments combined (p < 0.0001, Figures 7A, 7B and S7). In keeping with a previous report, mdx treatment with 40 mg/kg dantrolene alone lowers CK to some extent but not to the same degree as treatment with dantrolene and e23AON combined.13 However, the high degree of rescue induced by each dantrolene and phosphorodiamidate morpholino oligomer (PMO) alone precludes distinguishing between a synergistic versus additive effect.
To determine the effect of combination therapy on mdx muscle histopathology, we quantitated (1) ongoing regeneration of myofibers by assessing embryonic myosin heavy chain (eMHC) expression and (2) degeneration/regeneration by assessing myofiber centronucleation. In the mdx model, muscle injury leads to increases in regeneration/degneration, and eMHC and centronucleation are each anticipated to decrease with dystrophin rescue. eMHC and centronucleation were both decreased in response to e23AON treatment alone (Figures 8A, 8D, and S8).

Dantrolene co-administration caused a decrease in centronucleation in the diaphragm to a high degree of certainty when examined across all e23AON treatments combined (p = 0.017, Figures 8A, 8D, and S8). Although statistical significance was not observed when centronucleation in the quadriceps was analyzed independently, there was a trend toward less centronucleation when analyzed together (p = 0.066). Dantrolene, when co-administered with e23AON, is also observed to cause a decrease in eMHC-positive fibers relative to e23AON alone in the quadriceps (p = 0.021) and diaphragm (p = 0.025) to a high degree of certainty based on the multivariate analysis (Figures 8B–8D and S8). Meta-analysis of the p values from the quadriceps and diaphragm combined supports an effect from dantrolene/e23AON treatment relative to e23AON alone on both centronucleated fibers (p = 0.0087) and eMHC-positive fibers (p = 0.0045, Figure 4C). These findings demonstrate that dantrolene boost can impact mdx pathophysiology, which is predicted to impact muscle function, and highlights the potential of combination therapy to improve therapeutic outcome.

Meta-Analyses Show that Dantrolene Significantly Boosts the AON Effect on All Quantitative Outcomes

The levels of significance of dantrolene boost across both muscles are shown side by side in Table 1. Taken together, our meta-analyses demonstrate that dantrolene boosts the e23AON effect on all quantitative outcomes of exon skipping, dystrophin expression, and pathophysiology measured when considered across both muscles combined, with a high level of significance (p = 0.00012–0.0087).

**DISCUSSION**

Here, we provide preclinical mouse data in support of re-purposing dantrolene to boost AON-guided DMD exon skipping. Dantrolene is already FDA approved for both malignant hyperthermia and spasticity and has been used broadly in the pediatric population. When evaluated for dystrophin expression, dantrolene was dosed at 30–70 mg/kg/day. p values from the multivariate assessment of the effect of dantrolene on e23AON treatment for dystrophin immunofluorescence quantitation and dystrophin-positive fibers. p values from the statistical assessment of the additional contribution of dantrolene to e23AON treatment for exon 23 skipped/ (skipped + unskipped) transcript as measured by ddPCR. p values are from Friedman’s test, a two-way nonparametric ANOVA, and a meta-analysis of the results across muscles for dystrophin immunofluorescence quantitation. (D) Effect of dantrolene on e23AON sarcolemmal dystrophin expression as illustrated by representative images from the quadriceps and diaphragms of mdx mice after treatment with e23AON & dantrolene. Scale bar, 50 μm.
used in combination with e23AON, 30–70 mg/kg/day dantrolene modestly increased e23-skipped mRNA, dystrophin protein expression, and rescue of pathophysiology after 6 months of chronic dosing in the mdx DMD mouse model. We used a dosing scheme more compatible with human DMD treatment than our previous studies, which relied on 2X daily i.p. dantrolene injection, attempting to more closely approximate a regimen of chronic oral dosing of dantrium in humans.

Although no published study exactly recapitulates our dosing scheme, two published studies report a higher degree of dystrophin rescue in mdx mice than our previous studies, which relied on 2X daily i.p. dantrolene injection, attempting to more closely approximate a regimen of chronic oral dosing of dantrium in humans.

Figure 5. Dantrolene Boosts e23AON to Promote Rescue of Dystrophin Protein after Chronic Treatment

(A) Western blot demonstrating the effect of dantrolene on e23AON-induced expression of total dystrophin protein in mdx mice treated for 6 months. Protein from each muscle of mice in all treatments group was isolated and quantified independently. Dantrolene was dosed at 30–70 mg/kgiday. (B) Representative western blots for dystrophin protein expression from quadriceps are shown. C57BL/6 protein was loaded at 25%, 12.5%, and 6.25% dilutions (diluted in protein samples from mdx mice to serve as a standard). (C) p values from the multivariate assessment of the effect of dantrolene on e23AON treatment for dystrophin protein by western blot. p values are from Friedman’s test, a two-way nonparametric ANOVA, and a meta-analysis of the results across muscles.

Regardless, because we observed a significant dantrolene boost effect across a wide range of PMO doses, such differences do not greatly impact the conclusion reached that dantrolene has observed efficacy as a skip booster at a range of PMO doses and dystrophin induction. The modest 32%–37% relative fold change with dantrolene treatment reported in Table 1 is averaged across all e23AON concentrations tested, including no AON, which underestimates the true effect size at a given AON dose. There is an apparent correlation that at higher doses of e23AON, there was a large effect of dantrolene co-administration.

Mouse to human equivalence formulas would predict that a 30 mg/kg/week Exondys51 dosing in boys weighing 20 kg would be equivalent to 240 mg/kg weekly dosing in mice. However, the AON exon-skipping drug appears not to scale typically from mouse to dog using standard equivalence formulas based on surface area and therefore is unlikely to scale typically in humans. In our experiments, the 300 mg/kg e23AON dose induces 7.2% dystrophin, distributed across 12.6% of the quadriceps fibers. By comparison, ExonDys51 induces significantly less dystrophin in DMD boys, on average 0.93% (range, 0%–2.47%), distributed across 16% of fibers (range, 1.4%–33.5%). At 50 mg/kg e23AON, we observed, on average, 5.1% dystrophin distributed across 7.1% of quadriceps fibers, whereas 10 mg/kg yields 3.9% dystrophin across 3.4% of fibers. Although none of these doses perfectly approximate the reported data from humans treated with 30–50 mg/kg/week, based on measures of dystrophin rescue, we have demonstrated a dantrolene effect across doses that span a broad range of AON, including concentrations most likely to recapitulate approved dosing of 30 mg/kg/week Exondys51. Therefore, dantrolene promotes skipping activity in the mouse model and has high potential in humans when used in combination with

levels. Regardless, because we observed a significant dantrolene boost effect across a wide range of PMO doses, such differences do not greatly impact the conclusion reached that dantrolene has observed efficacy as a skip booster at a range of PMO doses and dystrophin induction. The modest 32%–37% relative fold change with dantrolene treatment reported in Table 1 is averaged across all e23AON concentrations tested, including no AON, which underestimates the true effect size at a given AON dose. There is an apparent correlation that at higher doses of e23AON, there was a large effect of dantrolene co-administration.

Mouse to human equivalence formulas would predict that a 30 mg/kg/week Exondys51 dosing in boys weighing 20 kg would be equivalent to 240 mg/kg weekly dosing in mice. However, the AON exon-skipping drug appears not to scale typically from mouse to dog using standard equivalence formulas based on surface area and therefore is unlikely to scale typically in humans. In our experiments, the 300 mg/kg e23AON dose induces 7.2% dystrophin, distributed across 12.6% of the quadriceps fibers. By comparison, ExonDys51 induces significantly less dystrophin in DMD boys, on average 0.93% (range, 0%–2.47%), distributed across 16% of fibers (range, 1.4%–33.5%). At 50 mg/kg e23AON, we observed, on average, 5.1% dystrophin distributed across 7.1% of quadriceps fibers, whereas 10 mg/kg yields 3.9% dystrophin across 3.4% of fibers. Although none of these doses perfectly approximate the reported data from humans treated with 30–50 mg/kg/week, based on measures of dystrophin rescue, we have demonstrated a dantrolene effect across doses that span a broad range of AON, including concentrations most likely to recapitulate approved dosing of 30 mg/kg/week Exondys51. Therefore, dantrolene promotes skipping activity in the mouse model and has high potential in humans when used in combination with
currently available Exondys51 dosing. However, it will be important to test dantrolene/Exondys51 efficacy in the context of a human DMD trial to establish safety and efficacy prior to wide adoption and implementation in clinical practice.

The pivotal Exondys51 trial used to support accelerated approval relied on 30–50 mg/kg weekly dosing in humans and is consistent with a functional benefit in boys with DMD. At accelerated approval, the FDA suggested that exploring higher and/or more frequent Exondys51 dosing to increase the amount of dystrophin induced and better observe clinical efficacy is necessary. However, increasing the frequency of dosing of Exondys51 is unlikely to be practical, and it is unclear if higher dosing is feasible from a toxicity perspective.41 AON modifications that promise better muscle cell uptake, such as peptide linkages, and that use skip boosting agents represent alternative approaches to increasing dystrophin levels. In addition to our identifying dantrolene boost activity,25 others have reported skip boosting using CELF2a inhibitors, 6-thioguanine, NOL8 protein, and carbohydrate-based infusions.40,42–45 However, dantrolene is the only FDA-approved drug with previous exposure in boys with DMD and a good safety profile.

We have previously published that dantrolene boosts AON exon 51 skipping in human patient fibroblast-derived myotube cultures.25 Our published findings showing that dantrolene can boost skipping in combination with either AON or 2-o-methyl AON chemistries may indicate that dantrolene boost is agnostic to AON chemistry.25 Dantrolene is an FDA-approved drug indicated for chronic use for spasticity (1.6–6.5 mg/kg/day) and acutely for malignant hyperthermia (4–8 mg/kg) and has been widely studied in multiple animal models and humans. It targets the RyR1, which is responsible for Ca²⁺ release from the sarcoplasmic reticulum (SR) and regulating levels of cytosolic and SR luminal Ca²⁺ levels essential for excitation-contraction coupling.

In the current study, we measured dantrolene serum levels to be an average of 0.26 mg/mL ± 0.18, which is at the low end of the known therapeutic range used in humans (0.37 to 1.24 mg/mL).46,51,52 Together with findings that other RyR calcium modulators, like RyCal S107, can also boost exon skipping, it is likely dantrolene boost activity results from RyR calcium modulation.53–55 Calcium regulation of alternative splicing has been described in other models.56–58 In DMD, RyR has been shown to be dysregulated and contributes to increased intracellular calcium and DMD pathology.5 As a potential means of controlling calcium-handling defects in DMD, Bertorini et al.59 administered 8 mg/kg/day dantrolene to 7 DMD boys over a 2-year period. In those studies, dantrolene was well tolerated in 6/7 patients; one boy experienced increased, but mild, muscle weakness that was reversed upon lowering the dose to 6 mg/kg/day. A trend toward reducing manual muscle testing deterioration was observed, and a statistically significant reduction in CK levels was reported. Although the data were insufficient to establish a clear functional benefit, this study demonstrates long-term treatment with dantrolene can be tolerated in children with DMD.

We demonstrated reduced CK levels in mdx mice treated with dantrolene alone, but observed no effect on any other measures of mdx histopathology or exon skipping in the absence of e23AON.

The pivotal Exondys51 trial used to support accelerated approval relied on 30–50 mg/kg weekly dosing in humans and is consistent with a functional benefit in boys with DMD. At accelerated approval, the FDA suggested that exploring higher and/or more frequent Exondys51 dosing to increase the amount of dystrophin induced and better observe clinical efficacy is necessary. However, increasing the frequency of dosing of Exondys51 is unlikely to be practical, and it is unclear if higher dosing is feasible from a toxicity perspective. AON modifications that promise better muscle cell uptake, such as peptide linkages, and that use skip boosting agents represent alternative approaches to increasing dystrophin levels. In addition to our identifying dantrolene boost activity, others have reported skip boosting using CELF2a inhibitors, 6-thioguanine, NOL8 protein, and carbohydrate-based infusions. However, dantrolene is the only FDA-approved drug with previous exposure in boys with DMD and a good safety profile.

We have previously published that dantrolene boosts AON exon 51 skipping in human patient fibroblast-derived myotube cultures. Our published findings showing that dantrolene can boost skipping in combination with either AON or 2-o-methyl AON chemistries may indicate that dantrolene boost is agnostic to AON chemistry. Dantrolene is an FDA-approved drug indicated for chronic use for spasticity (1.6–6.5 mg/kg/day) and acutely for malignant hyperthermia (4–8 mg/kg) and has been widely studied in multiple animal models and humans. It targets the RyR1, which is responsible for Ca²⁺ release from the sarcoplasmic reticulum (SR) and regulating levels of cytosolic and SR luminal Ca²⁺ levels essential for excitation-contraction coupling.

In the current study, we measured dantrolene serum levels to be an average of 0.26 µg/mL ± 0.18, which is at the low end of the known therapeutic range used in humans (0.37 to 1.24 µg/mL). Together with findings that other RyR calcium modulators, like RyCal S107, can also boost exon skipping, it is likely dantrolene boost activity results from RyR calcium modulation. Calcium regulation of alternative splicing has been described in other models. In DMD, RyR has been shown to be dysregulated and contributes to increased intracellular calcium and DMD pathology. As a potential means of controlling calcium-handling defects in DMD, Bertorini et al. administered 8 mg/kg/day dantrolene to 7 DMD boys over a 2-year period. In those studies, dantrolene was well tolerated in 6/7 patients; one boy experienced increased, but mild, muscle weakness that was reversed upon lowering the dose to 6 mg/kg/day. A trend toward reducing manual muscle testing deterioration was observed, and a statistically significant reduction in CK levels was reported. Although the data were insufficient to establish a clear functional benefit, this study demonstrates long-term treatment with dantrolene can be tolerated in children with DMD.

We demonstrated reduced CK levels in mdx mice treated with dantrolene alone, but observed no effect on any other measures of mdx histopathology or exon skipping in the absence of e23AON.
consistent with published data. In one published study in mdx mice, 6-week 40 mg/kg dantrolene treatment reduced both CK levels and some, but not all, measures of strength, despite no observed effect on histopathology. It is reasonable to anticipate that if there is a beneficial effect in humans, chronic administration will be necessary. Because we observed skip boosting activity at doses in the low range used chronically for spasticity and higher dosing has been reported to induce mild muscle weakness in some instances, it would be prudent to perform a dose-ranging trial in humans prior to routine use of combination therapy for DMD.

In our studies, dantrolene boosts dystrophin levels by as much as 1%–1.7% of normal levels and allows expression in an additional 4%–10% of the fibers at the most relevant AON doses. Our findings provide pre-clinical support and guidance for combination AON/dantrolene therapy for enhancement of Exondys51 or other skipping drugs in the research pipeline for DMD and perhaps other diseases to be targeted by exon skipping. Because Exondys51 and dantrolene are already FDA approved, our findings can be assessed rapidly in human trials, highlighting the value of screening FDA-approved drugs for combination therapies that promise greater efficacy.

MATERIALS AND METHODS

Long-Term Treatment Blinding

The present randomized, blinded, placebo-controlled study was performed on 180 mdx mice. Factorial randomization was used and mice were stratified into treatment groups based on animal age and weight and randomly assigned to each treatment group. 24 or 18 mdx mice aged 4–6 weeks were used in each group. Procedures involving all mdx mice were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of California, Los Angeles (UCLA). Individuals dosing the mice and performing data-generating assays were blinded for all assays. Once all the data were collected, the blind was lifted for the individual performing statistics.

Mice and Tissue Preparation

Procedures involving all mdx mice were approved by the IACUC of UCLA. For 3-week and 6-month experiments with systemic injections of e23AON, the quadriceps were harvested and the right muscle was frozen in OCT for sectioning and analysis by immunohistochemistry (IHC), whereas the left muscle was cut in half and snap frozen for analysis by western blot and ddPCR. For the diaphragm, one-half of the muscle was designated for IHC and one-fourth was designated for western blot and RT-PCR. Mice and chow were weighed weekly.

AON and Dantrolene Administration to mdx Mice

e23AON morpholino (5’-GGCCAAACCTCGGCTTACCTGAA AT-3’; provided by Sarepta Therapeutics) was injected intravenously (retro-orbitally) in 100 μL saline. For 3-week experiments, Revonto (dantrolene sodium NDC 27505-001-65; DSM Pharmaceuticals) was resuspended in water and administered by oral gavage in a 100-μL bolus twice daily. For 6-month experiments, control and experimental feed...
was formulated into 58YP chow at 0, 1,121, and 1,328 ppm. Dantrolene from capsules (NDC 0115-4433-1 GlobalRPH) (Lot 1000732) was incorporated into chow and irradiated (Newco Distributors) and mice were given ad libitum access to chow. To ensure continued exposure to target levels of dantrolene, mice were weighed at week 13 and chow dantrolene concentration was adjusted to 1,328 ppm, where appropriate. The amount of chow consumed was weighed weekly and dantrolene dose was adjusted by bodyweight.

RNA Isolation, qPCR, and ddPCR
Total RNA was isolated from frozen skeletal muscle with the Qiagen RNeasy Fibrous Tissue Kit and reverse transcribed to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad). The final concentration of digested total DNA was adjusted to fall within the linear range for the Poisson calculation for the expected number of droplets in the digital PCR. Each sample was partitioned into 15,000 droplets on a DG8 cartridge (Bio-Rad) and each droplet was amplified by PCR using the following protocol: initial denaturation step at 95°C for 10 min, 40 cycles of 94°C for 30 s, and 60°C for 30 s, followed by 98°C for 10 min. Primer-probe sets to assess specific full-length or skipped Dmd exon 23 mRNAs have been previously described. For amplification of exons from 22 to 24; the percentage of exon skipping was expressed as the total exon 23 skipped transcript as a percentage of total (skipped + unskipped) Dmd transcript. Samples were loaded onto the QX200 droplet reader, and ddPCR data were analyzed with QuantaSoft analysis software. The target concentration in each sample was expressed as copies per ng.

Measurement of Serum Creatine Kinase, γ-Glutamyl Transpeptidase, Creatinine, Total Bilirubin, and Blood Urea Nitrogen
Blood was collected by retro-orbital bleeding of the mice. After clotting, samples were spun at 6,000 rpm at 4°C. Serum was collected, snap frozen in liquid nitrogen, and stored at −80°C. Creatine kinase analysis was performed with the Genzyme Creatine Kinase kit (BioPacific Diagnostic). γ-glutamyl transpeptidase, creatinine, total bilirubin, and blood urea nitrogen measurements were performed by the UCLA Division of Laboratory Animal Medicine (DLAM) Pathology and Laboratory Medicine Services.

Measurement of Dantrolene Serum Levels
Blood was collected by retro-orbital bleeding of the mice. After clotting, samples were spun at 6,000 rpm at 4°C. Serum was collected, snap frozen in liquid nitrogen, and stored at −80°C. Dantrolene serum analysis was performed with the Dantrolene ELISA Kit (Neogen; Product #106319; Lot 140923). Samples were run in duplicate. A standard curve was run on each plate to ensure sensitivity of the assay (Figure S2B). Diluted dantrolene solution was used to generate a standard curve.

Western Blot Protocol
Total protein was isolated from flash-frozen quadriceps and diaphragms from the treated MDX and control C57 mice. Tissues were homogenized in Mito buffer (0.2 mM EDTA, 0.25 mM sucrose, and 10 mM tris-HCl [pH 7.4]) with protease/phosphatase inhibitor cocktail (Pierce) and deoxyribonucleoside/ribonucleoside and subjected to low-speed (3,000 × g) centrifugation for 10 min at 4°C. The supernatant was centrifuged at 100,000 × g (high-speed centrifugation) for 1 hr for isolation of membrane fraction. Isolated membranes and pellet after low-speed centrifugation were combined and resuspended in 300 mL extraction buffer (50 mM tris-HCl [pH 7.4], 7 M urea, 2 M thiourea, 4% 3-(3-cholamidopropyl)dimethylammonio)-1-propanesulfonate (CHAPS), 2% SDS, and 50 mM b-mercaptoethanol). Protein concentration was determined by 2-D Quant Kit (GE Healthcare Life Sciences).

40 μg total protein were run on a 6% polyacrylamide gel and transferred onto a nitrocellulose membrane for 2 hr at 4°C. The membrane was blocked for 1 hr in 5% milk and then incubated with MANDYS8 (Sigma) (anti-dystrophin), 1:400 in Tris-buffered saline with tween (TBS-T), hVin-1 (Sigma), 1:5,000 in TBST (antivinculin), and a skeletal muscle membrane protein not associated with the DGC that was used as a loading control.

---

Table 1. Friedman’s Test, Two-Way Nonparametric ANOVA, of the Addition of Dantrolene to e23AON Treatment for Study Outcomes and Meta-Analyses of the p Values across Muscle Types

| Outcome Measure | n   | Relative Fold Change with Dantrolene Treatment | Serum CK (p Value) | Meta-Analysis (p Value) |
|-----------------|-----|-----------------------------------------------|-------------------|------------------------|
| Exon 23 skipped/(skipped + unskipped) transcript (%) | 124 | 1.37                                          | 0.012             | 0.00008                |
| Dystrophin immunofluorescence quantitation (% C57) | 152 | 1.33                                          | 0.0032            | 0.026                  |
| Dystrophin-positive fibers (%) | 154 | 1.42                                          | 0.0069            | 0.0035                 |
| Dystrophin protein by western blot (%C57) | 131 | 1.23                                          | 0.0054            | –                      |
| Centronucleated fibers (%) | 47  | 0.97                                          | 0.0066            | 0.017                  |
| cMHC-positive fibers (%) | 47  | 0.83                                          | 0.021             | 0.025                  |

Shown is a summary of statistical analysis described in Figures 3B, 4C, 5C, 7B, and 8D.
For analysis, dystrophin protein levels were normalized to the loading and then pooled across treatment groups to determine the average dystrophin rescue. Serial dilutions of C57 sample into untreated MDX sample were run simultaneously. All western data included were run through quality control, as defined by linearity of dilution of C57 controls. The average densitometry value for 100% of dystrophin in C57 was calculated as the mean of the densitometry values of C57 serial dilutions multiplied by the dilution factor. Densitometry analysis was performed with the ImageLab 5.1 gel documentation system (Bio-Rad).

Histology and Immunofluorescence

IHC was performed on unfixed 10-mm tissue sections using the MouseOnMouse kit (Vector Labs). IHC assessment used the following primary antibodies: MANDYS8 (dystrophin rod domain), Ab15277 (dystrophin C terminus; Abcam), and Manex1A (dystrophin N terminus; Developmental Studies Hybridoma Bank). α-Sarcoglycan was detected with NCL-α-SARC (Novocastra), and β-dystroglycan was detected with NCL-β-DG (Novocastra), eMHC (DSHB; BF-G6-e), and DNA with DAPI. Secondary labeling was performed with fluorescein isothiocyanate (FITC) anti-mouse or FITC anti-rabbit (Vector Labs). Sections were mounted in Vectashield Mounting Medium (Vector Labs). Fluorescent images were acquired and analyzed using Ariel SL-50 (Applied Imaging, San Jose, CA). The Ariel scanner is based on an Olympus BX61 microscope with motorized stage and autofocus capabilities, equipped with a black and white video camera (Jai CVM2CL). Scanning and analyses were performed through the Translational Pathology Core Laboratory, Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA. For quantifying dystrophin immunofluorescence, the minimum threshold was placed above background level for all sections. Analytical readouts included area of immunofluorescence (IFL) signal (area of signal above the signal threshold) and total area of the section. The total area of positive pixels above the minimum threshold per muscle section was counted using AxiolVision Rel.4.6.3.0 acquisition software. Each sample’s dystrophin immunofluorescence levels are expressed as a percentage of positive pixels in C57 (100%). For quantifying dystrophin-positive fibers, the minimum threshold was placed above background level for all sections. For each sample, fibers were counted across the entire section. Dystrophin-positive fibers were defined as fibers that had sarcolemmal dystrophin expression above background and surrounding >75%–80% of each fiber. For both measurements, all of our readings were well below the maximal intensity threshold (pixel saturation was avoided). For detecting DGC-associated proteins by IHC, 2 mice from each treatment group, including non-treated mdx controls, were selected and the samples were blinded. Samples were stained and entire cross-sections were visualized. While blinded, representative fields for each sample were taken. A subset of these images is included as Figure 6. For quantifying centronucleation, eMHC-positive fibers, diaphragms, and quadriceps from the 3 to 6 mice per treatment group, which had total dystrophin levels by western blot near the median, were selected. The average percentage of fibers with centrally located nuclei in the diaphragm per group was determined by counting entire muscle cross-sections. For quantifying eMHC-positive fibers, quadriceps/diaphragms from 6 mice per group, which had total dystrophin levels by western blot near the median, were selected. The total number of eMHC-positive fibers were counted and compared to the total number of muscle fibers per section. For pathology, a standard protocol was used for H&E staining. All mouse livers, hearts, and kidneys were reviewed blindly by a certified pathologist.

Statistical Analysis

We selected to test whether dantrolene makes an additional contribution to the outcomes beyond E23AON using a 2-way ANOVA with interactions. However, we observed that the outcomes data are not normally distributed, and performed a nonparametric version of analysis using Friedman’s test using SAS software (version 9.4, SAS Institute, Cary, NC). We ran each analysis on the ranks of the observations for each of the 7 traits (or assays). Quadriceps, diaphragm, and serum were analyzed separately. Each test included E23AON first, followed by dantrolene and the possibility of their interaction. None of the interactions were significant. The separate outcome results were combined by meta-analyses across muscle types, resulting in tests of 6 non-independent traits. A 0.01 level of significance was set to account for multiple testing of 6 traits that are not independent. For each outcome, E23AON was highly significantly (p < 0.0001), except for centronucleated fibers in the quadriceps (p < 0.04) (data not shown). Table 1 presents the p values for dantrolene for each of the outcomes. A standard protocol was used for H&E staining. The average percentage of fibers with centrally located nuclei in the diaphragm per group was determined by counting 750–1,000 fibers from the 3 mice per group, which had total dystrophin levels by western blot nearest the median. All mouse livers, hearts, and kidneys were reviewed blindly.

SUPPLEMENTAL INFORMATION

Supplemental Information includes eight figures and can be found with this article online at https://doi.org/10.1016/j.omtn.2018.02.002.

AUTHOR CONTRIBUTIONS

D.W.W. led the implementation of mouse experiments and performed the RNA skipping quantification experiments, pathophysiology experiments, and serum biomarker experiments. E.I.M. performed muscle sectioning and quantitative immunohistochemistry and western blotting for dystrophin. Y.B.N. performed pathological experiments, and serum biomarker experiments. M.C.M. and S.F.N. conceived the project, designed the experiments, and supervised the entire study. M.J.S. helped implement the mouse dosing together with M.C.M. and S.F.N. R.M.C. conceived the statistical model and meta-analyses used in the study. M.C.M. and S.F.N. wrote the manuscript with input from the other authors. M.C.M. and S.F.N. are inventors on a pending patent on identification of small molecules that enhance exon skipping filed by UCLA.

CONFLICTS OF INTERESTS

S.F.N., M.C.M., and M.M. are inventors on a pending patent on identification of small molecules that enhance exon skipping filed by UCLA.
ACKNOWLEDGMENTS

We thank J. Wen and L. Martinez for providing technical support. We thank F. Barthélémé for critical reading and providing expert input throughout the project. Scanning, quantitative analysis of muscle cross-sections, and staining and histological analysis of organs were performed at the UCLA Translational Pathology Core Laboratory. This work was primarily funded from grants from the NIH (1T32AR659721A1) and the California Institute of Regenerative Medicine (TRX-05426). Support of the research was also provided by the UCLA Muscular Dystrophy Core Center (NIH 5P30AR057230) within the Center for Duchenne Muscular Dystrophy at UCLA.

REFERENCES

1. Mah, J.K., Kornigut, L., Dykejman, J., Day, L., Pringsheim, T., and Jette, N. (2014). A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromusc. Disord. 24, 482–491.
2. Emery, A.E. (2002). The muscular dystrophies. Lancet 359, 687–695.
3. Birels, S., Miyahara, E.H., Copin, S.D., Carlig, P.M., and Rando, T.A. (2014). A Wnt-TGFβ2 axis induces a fibrogenic program in muscle stem cells from dystrophic mice. Sci. Transl. Med. 6, 267ra176.
4. Tanahita, J., and Takeda, S. (2016). [Changes in cytosolic Ca2+ dynamics associated with muscular dystrophy]. Clin. Calcium 26, 1677–1683.
5. Bellinger, A.M., Reiken, S., Carlson, C., Mongillo, M., Liu, X., Rothman, L., Matecki, S., Lacampagne, A., and Marks, A.R. (2009). Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nat. Med. 15, 325–330.
6. Samaha, F.J., and Quinlan, J.G. (1996). Dystrophinopathies: clarification and complications. J. Child Neurol. 11, 13–20.
7. Emery, A.E., and Skinner, R. (1976). Clinical studies in benign (Becker type) X-linked muscular dystrophy. Adv. Drug Deliv. Rev. 87, 104–107.
8. Yokota, T., Lu, Q.L., Partridge, T., Kobayashi, M., Nakamura, A., Takeda, S., and Hoffman, E. (2009). Efficacy of systemic morpholino exon skipping in Duchenne dystrophy dogs. Ann. Neurol. 65, 667–676.
9. Altor, J., Lou, F., Kornigut, A., Yin, H., Rosenfeld, J., Wilton, S.D., Partridge, T.A., and Lu, Q.L. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat. Med. 12, 175–177.
10. Lu, Q.L., Nystrom, B., Fox, B., Barsky, M., Abbs, S., Nihoyannopoulos, P., et al. (2009). Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8, 918–928.
11. Mendell, J.R., Rodino-Klapac, L.R., Sahenk, Z., Roush, K., Bird, L., Lowes, L.P., Alfano, L., Gomez, A.M., Lewis, S., Kota, J., et al.; Etepliren Study Group (2013). Etepliren for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637–647.
12. Mendell, J.R., Goemans, N., Lowes, L.P., Alfano, L.N., Berry, K., Shao, J., Kaye, E.M., and Mercuri, E.; Etepliren Study Group and Telethon Foundation DMD Italian Network (2016). Longitudinal effect of etepliren versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79, 257–271.
13. Hoffman, E.P., Fischbeck, K.H., Brown, R.H., Johnson, M., Medori, R., Lou, J.D., Harris, J.B., Waterston, R., Brooke, M., Specht, L., et al. (1998). Characterization of dystrophin in muscle biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N. Engl. J. Med. 338, 1363–1368.
14. van den Bergen, J.C., Wobbe, B.H., Janson, A.A., van Dunen, S.G., Hulsken, M.A., Ginjaa, H.B., van Deutekom, J.C., Aartsma-Rus, A., Kan, H.E., and Verschaeren, J.J. (2014). Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry 85, 747–753.
15. van Putten, M., Hulsken, M., Young, C., Nadarajah, V.D., Heemskerk, H., van der Weerd, L., ’t Hoen, P.A., van Ommen, G.J., and Aartsma-Rus, A.M. (2013). Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. FASEB J. 27, 2484–2495.
16. Kendall, G.C., Mochnikova, E.I., Moran, M., Sejbuk, N.E., Wang, D.W., Silva, O., Wang, R.T., Martinez, L., Lu, Q.L., Damoiseaux, R., et al. (2012). Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Sci. Transl. Med. 4, 164ra40.
17. Malea, A., Sharp, P.S., Graham, I.R., Arechavala-Gomeza, V., Foster, K., Muntoni, F., Wells, D.J., and Dickson, G. (2011). Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice. Mol. Ther. 19, 345–354.
18. Wu, B., Xiao, B., Cloer, C., Shabab, M., Salo, A., Lu, P., Li, J., Nagaraju, K., Xiao, X., and Lu, Q.L. (2011). One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol. Ther. 19, 576–583.
19. Kilkenny, C., Parsons, N., Cadyzsewski, E., Festing, M.F., Cuthill, I.C., Fry, D., Hutton, J., and Altman, D.G. (2009). Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One 4, e7824.
20. Friedman, M. (1939). A correction: The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J. Am. Stat. Assoc. 34, 109.
21. Friedman, M. (1957). The use of ranks to avoid the assumption of normality implicit in the analysis of variance. J. Am. Stat. Assoc. 32, 675–701.
22. Quinn, J.L., Huyhn, T., Uasoosontrakchoo, K., Tatem, K., Phadde, A., van der Meulen, J.H., Yu, Q., and Nagaraju, K. (2013). Effects of dantrolene therapy on disease phenotype in dystrophic deficient mdx mice. PLoS Curr. 5.
23. Emwere, E.K., Boudreault, L., Hollbrook, J., Timusk, K., Earl, N., LaCasse, E., Renaud, J.M., and Kornek, R.G. (2013). Loss of cLAP1 attenuates soleus muscle pathology and improves diaphragm function in mdx mice. Hum. Mol. Genet. 22, 867–878.
24. Karpati, G., Carpenter, S., and Prescott, S. (1988). Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 11, 795–803.
25. Malea, A., Thorogood, F.C., Dickson, G., and Graham, I.R. (2009). Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum. Gene Ther. 20, 955–965.
26. Jansen, P.M., Murray, I.D., Schill, K.E., Rastogi, N., Schultz, E.J., Tran, T., Raman, S.V., and Rafael-Fortney, I.A. (2014). Prendisiline attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and saponinolate in the mdx mouse model of Duchenne muscular dystrophy. PLoS One 9, e88360.
36. Kobayashi, Y.M., Rader, E.P., Crawford, R.W., and Campbell, K.P. (2012). Endpoint measures in the mdx mouse relevant for muscular dystrophy pre-clinical studies. Neuromuscul. Disord. 22, 34–42.

37. Banks, G.B., Combs, A.C., Odom, G.L., Bloch, R.J., and Chamberlain, J.S. (1944). Muscle structure influences utrophin expression in mdx mice. PLoS Genet. 10, e1004341.

38. Dantrolene sodium [package insert]. 2011, JHP Pharmaceuticals, LLC: Rochester, MI.

39. Food and Drug Administration Center for Drug Evaluation and Research (CDER) (1983). Effect of dantrolene on neuro muscular block by d-tubocurarine and subsequent antagonism by neostigmine in the rabbit. Anesthesiology 52, 126–130.

40. Moulton, H.M., and Moulton, J.D. (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim. Biophys. Acta 1798, 2356–2363.

41. ClinicalTrials.gov. (2016). Safety and dose finding study of NS-065/NCNP-01 in boys with Duchenne muscular dystrophy (DMD). https://clinicaltrials.gov/ct2/show/NCT02740972?term=exon+skipping&cond=DMD&draw=2&rank=18.

42. Han, G., Gu, B., Cao, L., Gao, X., Wang, Q., Seow, Y., Zhang, N., Wood, M.J., and Yin, H. (2016). Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat. Commun. 7, 10981.

43. Martone, J., Briganti, F., Legnini, I., Morlando, M., Picillo, E., Sthandier, O., Politano, L., and Bozzoni, I. (2016). The lack of the Celf2a splicing factor converts a Duchenne genotype into a Becker phenotype. Nat. Commun. 7, 10488.

44. Hu, Y., Wu, B., Zillmer, A., Lu, P., Benrashid, E., Wang, M., Doran, T., Shaban, M., Xu, X., Uchinoumi, H., Okuda, S., Yamamoto, T., et al. (2009). Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53, 1993–2005.

45. Kobayashi, S., Yano, M., Suetomi, T., Ono, M., Tateishi, H., Mochnzik, M., Xu, X., Uchinoumi, H., Okuda, S., Yamamoto, T., et al. (2009). Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53, 1993–2005.

46. Flewellen, E.H., Nelson, T.E., Jones, W.P., Arens, J.F., and Wagner, D.L. (1983). Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59, 275–280.

47. Meyer, W.J., Bakker, H., Kok, J.J., Agoston, S., and Wesseling, H. (1981). The effect of dantrolene sodium in relation to blood levels in spastic patients after prolonged administration. J. Neurol. Neurosurg. Psychiatry 44, 334–339.

48. Kobayashi, S., Bannister, M.L., Gangopadhyay, J.P., Hamada, T., Parness, J., and Ikemoto, N. (2005). Dantrolene stabilizes domain interactions within the ryanodine receptor. J. Biol. Chem. 280, 6580–6587.

49. Hu, Y., Wu, B., Zillmer, A., Lu, P., Benrashid, E., Wang, M., Doran, T., Shaban, M., Xu, X., Uchinoumi, H., Okuda, S., Yamamoto, T., et al. (2009). Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53, 1993–2005.

50. Meyer, W.J., Mols-Thurkow, I., Scaf, A.H., Sargo, S., and Wesseling, H. (1979). The effect of dantrolene sodium on rat skeletal muscle in relation to the plasma concentration. Eur. J. Pharmacol. 53, 335–342.

51. Flewelen, E.H., Nelson, T.E., Jones, W.P., Arens, J.F., and Wagner, D.L. (1983). Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59, 275–280.

52. Flewellen, E.H., Nelson, T.E., Jones, W.P., Arens, J.F., and Wagner, D.L. (1983). Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59, 275–280.

53. Kobayashi, S., Yano, M., Suetomi, T., Ono, M., Tateishi, H., Mochnzik, M., Xu, X., Uchinoumi, H., Okuda, S., Yamamoto, T., et al. (2009). Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53, 1993–2005.

54. Kobayashi, S., Bannister, M.L., Gangopadhyay, J.P., Hamada, T., Parness, J., and Ikemoto, N. (2005). Dantrolene stabilizes domain interactions within the ryanodine receptor. J. Biol. Chem. 280, 6580–6587.

55. Hu, Y., Wu, B., Zillmer, A., Lu, P., Benrashid, E., Wang, M., Doran, T., Shaban, M., Xu, X., Uchinoumi, H., Okuda, S., Yamamoto, T., et al. (2009). Dantrolene, a therapeutic agent for malignant hyperthermia, markedly improves the function of failing cardiomyocytes by stabilizing interdomain interactions within the ryanodine receptor. J. Am. Coll. Cardiol. 53, 1993–2005.

56. Mannino, J.L., Kim, W., Wernick, M., Nguyen, S.V., Braquet, R., Adamson, A.W., Den, Z., Batzer, M.A., Collins, C.C., and Brown, K.D. (2001). Evidence for alternate splicing within the mRNA transcript encoding the DNA damage response kinase ATR. Gene 272, 35–43.

57. Flewelen, E.H., Nelson, T.E., Jones, W.P., Arens, J.F., and Wagner, D.L. (1983). Dantrolene dose response in awake man: implications for management of malignant hyperthermia. Anesthesiology 59, 275–280.

58. Xie, J., and Black, D.L. (2001). A CaMK IV responsive RNA element mediates depolarization-induced alternative splicing of ion channels. Nature 410, 936–939.

59. An, P., and Grabowski, P.J. (2007). Exon silencing by UAGG motifs in response to neuronal excitation. PLoS Biol. 5, e36.

60. Gebski, B.L., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 13, 2503–2507.

61. Bertorini, T.E., Palmieri, G.M., Grifin, J., Igarashi, M., Hinton, A., and Karas, J.G. (1991). Effect of dantrolene in Duchenne muscular dystrophy. Muscle Nerve 14, 503–507.

62. Quinlan, J.G., Johnson, S.R., and Samaha, F.J. (1990). Dantrolene normalizes serum creatine kinase in MDX mice. Muscle Nerve 13, 268–269.

63. Allen, G.C., Cattran, C.B., Peterson, R.G., and Lalande, M. (1988). Plasma levels of dantrolene following oral administration in malignant hyperthermia-susceptible patients. Anesthesiology 69, 900–904.

64. Gubski, R.L., Mann, C.J., Fletcher, S., and Wilton, S.D. (2003). Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum. Mol. Genet. 12, 1801–1811.

65. Hindson, C.M., Chevillet, J.R., Briggs, H.A., Gallichotte, E.N., Rui, I.K., Hindson, B.J., Vessella, R.L., and Tewari, M. (2013). Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10, 1003–1005.